{"success":true,"data":{"pressRelease":{"id":"162550","rtpr_id":"nPn49wwVfa-20261006","ticker":"PFE","exchange":"NYSE","all_tickers":["PFE","4503"],"title":"Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026","author":"PR Newswire","published_at":"2026-10-06T23:30:00.045Z","article_body":"Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026\nPR Newswire\n\nTOKYO, Oct. 6, 2026\n\n–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable\nsurvival benefit in advanced bladder cancer –\n\n– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in\nshaping gastric cancer treatment decisions –\n\nTOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President\nand CEO: Naoki Okamura, \"Astellas\") today announced that 21 abstracts from its\noncology portfolio will be presented at the European Society for Medical\nOncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid,\nSpain. The presentations span prostate, urothelial, gastric/gastroesophageal\njunction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment\nto advancing standards of care and pursuing new scientific approaches designed\nfor cancers where significant unmet need remains.\n\nMoitreyee Chatterjee-Kishore, Ph.D., MBA, Executive Vice President and Head of\nOncology Development, Astellas:\n\"Standards of care do not change by accident. The data being presented at ESMO\n2026 demonstrate how a deep understanding of disease biology and\ndifferentiated modalities is helping advance care for patients with bladder,\ngastric, and prostate cancers, including through approaches such as\nPADCEV™ (enfortumab vedotin) plus pembrolizumab, VYLOY™ (zolbetuximab),\nand XTANDI™ (enzalutamide). We are building upon this knowledge to develop\nthe next generation of therapeutic options for cancers where unmet needs\nremain and look forward to engaging in discussions about this work at the\ncongress.\"\n\nHighlights from Astellas' ESMO 2026 presentations include:\n\n * Enfortumab vedotin plus pembrolizumab presentations include the longest\nfollow-up reported to date in locally advanced or metastatic urothelial\ncancer, along with analyses across patient subgroups and treatment settings.\nAdditional presentations include trials in progress exploring bladder\npreservation in muscle-invasive bladder cancer.\n * Zolbetuximab presentations examine CLDN18.2 assessment, patient identification\nand real-world use, reinforcing the growing body of evidence supporting\nCLDN18.2-guided treatment decisions in gastric and GEJ cancers.\n * Pipeline presentations feature trials-in-progress across Astellas'\ninvestigational programs, including Phase 3 trials of setidegrasib in KRAS\nG12D-mutated pancreatic and non-small cell lung cancers, a Phase 1 trial of\nASP5834 in KRAS-mutated or amplified solid tumors, and a Phase 1b/2 trial of\nASP546C in CLDN18.2-expressing solid tumors. Together, these investigational\nstudies illustrate Astellas' continued investment in advancing new approaches\naimed at overcoming challenges that have limited progress in hard-to-treat\ncancers.\nAdditional details on Astellas' presentations at ESMO 2026 are included below.\n Presentation Title                                      Lead Author          Presentation Details\n Enfortumab vedotin\n EV-103 DE/Cohort A and Cohort K Final                   J. P. Maroto Rey     Type: Rapid oral\n Analysis: Enfortumab vedotin with or                                         Abstract number: 4740RO\n without pembrolizumab as first-line                                          Date/time: Saturday, October 24,\n treatment for cisplatin (cis)-ineligible locally                             10:15-11:45\n advanced or metastatic urothelial\n carcinoma: long-term follow-up analysis\n from EV-103 cohorts DE/A and K\n EV-302 Comorbidities (DCO3):                            S. S. Sridhar        Type: Poster\n Enfortumab vedotin plus pembrolizumab for                                    Abstract number: 4761P\n previously untreated locally advanced or                                     Date/time: Friday, October 23,\n metastatic urothelial carcinoma: updated                                     15:15-16:00\n exploratory analysis of EV-302 in older\n patients and those with comorbidities\n EV-302 Clinical Subgroups (DCO3):                       J. Bedke             Type: Poster\n Enfortumab vedotin + pembrolizumab in                                        Abstract number: 4760P\n previously untreated locally advanced or                                     Date/time: Friday, October 23,\n metastatic urothelial cancer: exploratory                                    15:15-16:00\n analyses based on disease-related\n characteristics from EV-302\n EVOLVE 3: Real-world treatment patterns                 F. Joly              Type: ePoster\n in patients with locally advanced and\n metastatic urothelial cancer in France\n EV-303/KN-905 ITT3: Perioperative                       A. Ullén             Type: Proffered paper session\n pembrolizumab or enfortumab vedotin plus                                     Abstract number: 4733O\n pembro in participants with muscle-invasive                                  Date/time: Friday, October 23,\n bladder cancer who are cisplatin-ineligible:                                 13:30-15:00\n ad hoc analysis from KEYNOTE-905\n EV-304/KN-B15 ctDNA: ctDNA analysis of                  J. Chatzkel          Type: Proffered paper session\n the phase 3 KEYNOTE-B15 trial:                                               Abstract number: 4734O\n neoadjuvant and adjuvant enfortumab                                          Date/time: Friday, October 23,\n vedotin + pembrolizumab for participants                                     13:30-15:00\n with muscle-invasive bladder cancer who\n are eligible for cisplatin\n EV-304/KN-B15 ePRO: Health-related                      A. Gómez De Liaño    Type: Rapid oral\n quality of life with neoadjuvant and adjuvant                                Abstract number: 4738RO\n enfortumab vedotin plus pembrolizumab in                                     Date/time: Saturday, October 24,\n participants (pts) with muscle-invasive                                      10:15-11:45\n bladder cancer eligible for cisplatin in the\n phase 3 KEYNOTE-B15 study\n EV-209 TiP: EV-209: an open-label, single-arm,          Thomas Powles        Type: Poster\n phase 2 study of enfortumab vedotin plus                                     Abstract number: 4769TiP\n pembrolizumab for bladder preservation in                                    Date/time: Friday, October 23,\n patients with muscle-invasive bladder cancer                                 15:15-16:00\n eligible for radical cystectomy\n EV-309 TiP: EV-309: an open-label,                      Matthew D. Galsky    Type: Poster\n randomized, phase 3 study of enfortumab                                      Abstract number: 4770TiP\n vedotin plus pembrolizumab for bladder                                       Date/time: Friday, October 23,\n preservation in patients with muscle-invasive                                15:15-16:00\n bladder cancer\n Enzalutamide\n Adelpi REALIZE: High-risk biochemically                 A. Merseburger       Type: ePoster\n recurrent (hrBCR) hormone sensitive                                          Abstract number: 2063eP\n prostate cancer (PC): European real-world                                    Date/time: N/A\n (RW) evidence on risk stratification, PSMA\n PET use, and physician practices\n AMNOG NMA in mHSPC: Network meta-analysis               C. Ohlmann           Type: Poster\n (NMA) on the safety of androgen receptor pathway                             Abstract number: 2295P\n inhibitors (ARPIs) in patients with metastatic                               Date/time: Friday, October 23,\n hormone-sensitive prostate cancer (mHSPC) from                               15:15-16:00\n German AMNOG dossiers\n CASPER: Outcomes of enzalutamide                        B. Shayegan          Type: ePoster\n (ENZ) and apalutamide (APA) in metastatic                                    Abstract number: 2329eP\n hormone-sensitive prostate cancer                                            Date/time: N/A\n (mHSPC): a Canadian real-world (RW) study\n ARCHES/ARANOTE indirect safety                          S. Shariat           Type: Poster\n comparison: Indirect safety comparison of                                    Abstract number: 2294P\n enzalutamide (ENZA) and darolutamide                                         Date/time: Friday, October 23,\n (DARO) with androgen-deprivation therapy                                     15:15-16:00\n (ADT) in metastatic hormone-sensitive\n prostate cancer (mHSPC)\n EMBARK deep PSA response: Deep                          S. Freedland         Type: Poster\n prostate-specific antigen (PSA) response                                     Abstract number: 2293P\n by prior definitive treatment (tx) in patients                               Date/time: Friday, October 23,\n (pts) with high-risk biochemically recurrent                                 15:15-16:00\n prostate cancer (hrBCR): EMBARK post\n hoc analysis\n Zolbetuximab\n SPOTLIGHT ctDNA: ctDNA Assessment in                    K. Shitara           Type: Poster\n Patients with CLDN18.2+, HER2−, Locally                                      Abstract number: 2882P\n Advanced Unresectable or Metastatic (la/m)                                   Date/time: Sunday, October 25,\n Gastric or Gastroesophageal Junction                                         12:00-12:45\n Adenocarcinoma (G/GEJ a) in SPOTLIGHT\n Canadian PSP: Real-World Use of                         H. Karachiwala       Type: Poster\n Zolbetuximab Plus Chemotherapy (CTx) in                                      Abstract number: 2941P\n Patients With CLDN18.2+, HER2−, Locally                                      Date/time: Sunday, October 25,\n Advanced (LA) Unresectable or Metastatic                                     12:00-12:45\n Gastric or Gastroesophageal Junction\n Cancer (mGC/GEJC)  in a Canadian\n Patient Support Program (PSP)\n Pipeline\n Phase 3 PDAC TiP: A Phase 3, double-blind,              T. Macarulla         Type: Poster\n randomized trial of setidegrasib + mFOLFIRINOX                               Abstract number: 3190TiP\n or NALIRIFOX as first-line treatment for patients                            Date/time: Sunday, October 25,\n with metastatic pancreatic ductal adenocarcinoma                             12:00-12:45\n (PDAC) harboring KRAS G12D mutations: Trial in\n progress\n Phase 3 NSCLC TiP: Phase 3,                             F. Skoulidis         Type: ePoster\n randomized, open-label trial of setidegrasib                                 Abstract number: 2871eTiP\n vs docetaxel in patients with KRAS G12D-mutated                              Date/time: N/A\n locally advanced or metastatic non-small cell lung\n cancer (NSCLC) that progressed on or after\n platinum-based chemotherapy and checkpoint inhibitor\n (CPI) therapy: Trial in progress\n Phase 1b/2 TiP: Phase 1b/2 study of                     T. Macarulla         Type: ePoster\n ASP546C, a Claudin 18.2-targeting                                            Abstract number: 1133eTiP\n antibody-drug conjugate with a                                               Date/time: N/A\n topoisomerase 1 inhibitor payload, in\n patients with Claudin 18.2-expressing\n unresectable locally advanced or metastatic\n solid tumors\n FiH TiP: A phase 1 study of ASP5834 in                  S. Sen               Type: ePoster\n patients with locally advanced or metastatic                                 Abstract number: 1145eTiP\n solid tumors with Kirsten rat sarcoma viral                                  Date/time: N/A\n oncogene homologue (KRAS) mutations or\n amplifications\n Combination clinical data for mss CRC:                  V. Boni              Type: ePoster\n A phase 1/2 study of ASP1570 for locally                                     Abstract number: 1090eP\n advanced/metastatic microsatellite-stable                                    Date/time: N/A\n (MSS) colorectal cancer (CRC)\n\nAbout Astellas\nAstellas is a global life sciences company committed to turning innovative\nscience into value for patients. We provide transformative therapies in\ndisease areas that include oncology, ophthalmology, urology, immunology and\nwomen's health. Through our research and development programs, we are\npioneering new healthcare solutions for diseases with high unmet medical need.\nLearn more at www.astellas.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790973-1&h=2550917136&u=http%3A%2F%2Fwww.astellas.com%2F&a=www.astellas.com)\n.\n\nAbout PADCEV and the Pfizer, Astellas and MSD Collaboration\nSeagen and Astellas previously entered a clinical collaboration agreement with\nMSD to evaluate the combination of Seagen's and Astellas'\nPADCEV(TM) (enfortumab vedotin) and MSD's KEYTRUDA(®) (pembrolizumab) in\npatients with urothelial cancer. Pfizer Inc. successfully completed its\nacquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark\nof Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,\nRahway, NJ, USA (known as MSD outside of the United States and Canada).\n\nAbout XTANDI and the Pfizer/Astellas Collaboration\nIn October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and\nAstellas (TSE: 4503) entered into a commercial agreement to jointly develop\nand commercialize XTANDI(®) (enzalutamide) in the United States, while\nAstellas has responsibility for manufacturing and all additional regulatory\nfilings globally, as well as commercializing the product outside the United\nStates. Pfizer receives alliance revenues as a share of U.S. profits and\nreceives royalties on sales outside the U.S.\n\nCautionary Notes\nIn this press release, statements made with respect to current plans,\nestimates, strategies and beliefs and other statements that are not historical\nfacts are forward-looking statements about the future performance of Astellas.\nThese statements are based on management's current assumptions and beliefs in\nlight of the information currently available to it and involve known and\nunknown risks and uncertainties. A number of factors could cause actual\nresults to differ materially from those discussed in the forward-looking\nstatements. Such factors include, but are not limited to: (i) changes in\ngeneral economic conditions, and in laws and regulations, relating to\npharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays\nin new product launches, (iv) the inability of Astellas to market existing and\nnew products effectively, (v) the inability of Astellas to continue to\neffectively research and develop products accepted by customers in highly\ncompetitive markets, and (vi) infringements of Astellas' intellectual property\nrights by third parties. Information about pharmaceutical products (including\nproducts currently in development) which is included in this press release is\nnot intended to constitute an advertisement or medical advice.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/astellas-highlights-data-advancing-cancer-care-and-innovation-for-patients-with-hard-to-treat-cancers-at-esmo-2026-302900206.html\n(https://www.prnewswire.com/news-releases/astellas-highlights-data-advancing-cancer-care-and-innovation-for-patients-with-hard-to-treat-cancers-at-esmo-2026-302900206.html)\n\nSOURCE Astellas Pharma Inc.\n\n\n\nAstellas Pharma Inc., Corporate Communications, +81-3-3244-3201\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS426384/Astellas-Logo.jpg?id=OA2990473\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn49wwVfa-20261006","title":"Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026","author":"PR Newswire","ticker":"PFE","created":"2026-10-06T23:30:00.045Z","tickers":["PFE","4503"],"exchange":"NYSE","article_body":"Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026\nPR Newswire\n\nTOKYO, Oct. 6, 2026\n\n–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable\nsurvival benefit in advanced bladder cancer –\n\n– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in\nshaping gastric cancer treatment decisions –\n\nTOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President\nand CEO: Naoki Okamura, \"Astellas\") today announced that 21 abstracts from its\noncology portfolio will be presented at the European Society for Medical\nOncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid,\nSpain. The presentations span prostate, urothelial, gastric/gastroesophageal\njunction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment\nto advancing standards of care and pursuing new scientific approaches designed\nfor cancers where significant unmet need remains.\n\nMoitreyee Chatterjee-Kishore, Ph.D., MBA, Executive Vice President and Head of\nOncology Development, Astellas:\n\"Standards of care do not change by accident. The data being presented at ESMO\n2026 demonstrate how a deep understanding of disease biology and\ndifferentiated modalities is helping advance care for patients with bladder,\ngastric, and prostate cancers, including through approaches such as\nPADCEV™ (enfortumab vedotin) plus pembrolizumab, VYLOY™ (zolbetuximab),\nand XTANDI™ (enzalutamide). We are building upon this knowledge to develop\nthe next generation of therapeutic options for cancers where unmet needs\nremain and look forward to engaging in discussions about this work at the\ncongress.\"\n\nHighlights from Astellas' ESMO 2026 presentations include:\n\n * Enfortumab vedotin plus pembrolizumab presentations include the longest\nfollow-up reported to date in locally advanced or metastatic urothelial\ncancer, along with analyses across patient subgroups and treatment settings.\nAdditional presentations include trials in progress exploring bladder\npreservation in muscle-invasive bladder cancer.\n * Zolbetuximab presentations examine CLDN18.2 assessment, patient identification\nand real-world use, reinforcing the growing body of evidence supporting\nCLDN18.2-guided treatment decisions in gastric and GEJ cancers.\n * Pipeline presentations feature trials-in-progress across Astellas'\ninvestigational programs, including Phase 3 trials of setidegrasib in KRAS\nG12D-mutated pancreatic and non-small cell lung cancers, a Phase 1 trial of\nASP5834 in KRAS-mutated or amplified solid tumors, and a Phase 1b/2 trial of\nASP546C in CLDN18.2-expressing solid tumors. Together, these investigational\nstudies illustrate Astellas' continued investment in advancing new approaches\naimed at overcoming challenges that have limited progress in hard-to-treat\ncancers.\nAdditional details on Astellas' presentations at ESMO 2026 are included below.\n Presentation Title                                      Lead Author          Presentation Details\n Enfortumab vedotin\n EV-103 DE/Cohort A and Cohort K Final                   J. P. Maroto Rey     Type: Rapid oral\n Analysis: Enfortumab vedotin with or                                         Abstract number: 4740RO\n without pembrolizumab as first-line                                          Date/time: Saturday, October 24,\n treatment for cisplatin (cis)-ineligible locally                             10:15-11:45\n advanced or metastatic urothelial\n carcinoma: long-term follow-up analysis\n from EV-103 cohorts DE/A and K\n EV-302 Comorbidities (DCO3):                            S. S. Sridhar        Type: Poster\n Enfortumab vedotin plus pembrolizumab for                                    Abstract number: 4761P\n previously untreated locally advanced or                                     Date/time: Friday, October 23,\n metastatic urothelial carcinoma: updated                                     15:15-16:00\n exploratory analysis of EV-302 in older\n patients and those with comorbidities\n EV-302 Clinical Subgroups (DCO3):                       J. Bedke             Type: Poster\n Enfortumab vedotin + pembrolizumab in                                        Abstract number: 4760P\n previously untreated locally advanced or                                     Date/time: Friday, October 23,\n metastatic urothelial cancer: exploratory                                    15:15-16:00\n analyses based on disease-related\n characteristics from EV-302\n EVOLVE 3: Real-world treatment patterns                 F. Joly              Type: ePoster\n in patients with locally advanced and\n metastatic urothelial cancer in France\n EV-303/KN-905 ITT3: Perioperative                       A. Ullén             Type: Proffered paper session\n pembrolizumab or enfortumab vedotin plus                                     Abstract number: 4733O\n pembro in participants with muscle-invasive                                  Date/time: Friday, October 23,\n bladder cancer who are cisplatin-ineligible:                                 13:30-15:00\n ad hoc analysis from KEYNOTE-905\n EV-304/KN-B15 ctDNA: ctDNA analysis of                  J. Chatzkel          Type: Proffered paper session\n the phase 3 KEYNOTE-B15 trial:                                               Abstract number: 4734O\n neoadjuvant and adjuvant enfortumab                                          Date/time: Friday, October 23,\n vedotin + pembrolizumab for participants                                     13:30-15:00\n with muscle-invasive bladder cancer who\n are eligible for cisplatin\n EV-304/KN-B15 ePRO: Health-related                      A. Gómez De Liaño    Type: Rapid oral\n quality of life with neoadjuvant and adjuvant                                Abstract number: 4738RO\n enfortumab vedotin plus pembrolizumab in                                     Date/time: Saturday, October 24,\n participants (pts) with muscle-invasive                                      10:15-11:45\n bladder cancer eligible for cisplatin in the\n phase 3 KEYNOTE-B15 study\n EV-209 TiP: EV-209: an open-label, single-arm,          Thomas Powles        Type: Poster\n phase 2 study of enfortumab vedotin plus                                     Abstract number: 4769TiP\n pembrolizumab for bladder preservation in                                    Date/time: Friday, October 23,\n patients with muscle-invasive bladder cancer                                 15:15-16:00\n eligible for radical cystectomy\n EV-309 TiP: EV-309: an open-label,                      Matthew D. Galsky    Type: Poster\n randomized, phase 3 study of enfortumab                                      Abstract number: 4770TiP\n vedotin plus pembrolizumab for bladder                                       Date/time: Friday, October 23,\n preservation in patients with muscle-invasive                                15:15-16:00\n bladder cancer\n Enzalutamide\n Adelpi REALIZE: High-risk biochemically                 A. Merseburger       Type: ePoster\n recurrent (hrBCR) hormone sensitive                                          Abstract number: 2063eP\n prostate cancer (PC): European real-world                                    Date/time: N/A\n (RW) evidence on risk stratification, PSMA\n PET use, and physician practices\n AMNOG NMA in mHSPC: Network meta-analysis               C. Ohlmann           Type: Poster\n (NMA) on the safety of androgen receptor pathway                             Abstract number: 2295P\n inhibitors (ARPIs) in patients with metastatic                               Date/time: Friday, October 23,\n hormone-sensitive prostate cancer (mHSPC) from                               15:15-16:00\n German AMNOG dossiers\n CASPER: Outcomes of enzalutamide                        B. Shayegan          Type: ePoster\n (ENZ) and apalutamide (APA) in metastatic                                    Abstract number: 2329eP\n hormone-sensitive prostate cancer                                            Date/time: N/A\n (mHSPC): a Canadian real-world (RW) study\n ARCHES/ARANOTE indirect safety                          S. Shariat           Type: Poster\n comparison: Indirect safety comparison of                                    Abstract number: 2294P\n enzalutamide (ENZA) and darolutamide                                         Date/time: Friday, October 23,\n (DARO) with androgen-deprivation therapy                                     15:15-16:00\n (ADT) in metastatic hormone-sensitive\n prostate cancer (mHSPC)\n EMBARK deep PSA response: Deep                          S. Freedland         Type: Poster\n prostate-specific antigen (PSA) response                                     Abstract number: 2293P\n by prior definitive treatment (tx) in patients                               Date/time: Friday, October 23,\n (pts) with high-risk biochemically recurrent                                 15:15-16:00\n prostate cancer (hrBCR): EMBARK post\n hoc analysis\n Zolbetuximab\n SPOTLIGHT ctDNA: ctDNA Assessment in                    K. Shitara           Type: Poster\n Patients with CLDN18.2+, HER2−, Locally                                      Abstract number: 2882P\n Advanced Unresectable or Metastatic (la/m)                                   Date/time: Sunday, October 25,\n Gastric or Gastroesophageal Junction                                         12:00-12:45\n Adenocarcinoma (G/GEJ a) in SPOTLIGHT\n Canadian PSP: Real-World Use of                         H. Karachiwala       Type: Poster\n Zolbetuximab Plus Chemotherapy (CTx) in                                      Abstract number: 2941P\n Patients With CLDN18.2+, HER2−, Locally                                      Date/time: Sunday, October 25,\n Advanced (LA) Unresectable or Metastatic                                     12:00-12:45\n Gastric or Gastroesophageal Junction\n Cancer (mGC/GEJC)  in a Canadian\n Patient Support Program (PSP)\n Pipeline\n Phase 3 PDAC TiP: A Phase 3, double-blind,              T. Macarulla         Type: Poster\n randomized trial of setidegrasib + mFOLFIRINOX                               Abstract number: 3190TiP\n or NALIRIFOX as first-line treatment for patients                            Date/time: Sunday, October 25,\n with metastatic pancreatic ductal adenocarcinoma                             12:00-12:45\n (PDAC) harboring KRAS G12D mutations: Trial in\n progress\n Phase 3 NSCLC TiP: Phase 3,                             F. Skoulidis         Type: ePoster\n randomized, open-label trial of setidegrasib                                 Abstract number: 2871eTiP\n vs docetaxel in patients with KRAS G12D-mutated                              Date/time: N/A\n locally advanced or metastatic non-small cell lung\n cancer (NSCLC) that progressed on or after\n platinum-based chemotherapy and checkpoint inhibitor\n (CPI) therapy: Trial in progress\n Phase 1b/2 TiP: Phase 1b/2 study of                     T. Macarulla         Type: ePoster\n ASP546C, a Claudin 18.2-targeting                                            Abstract number: 1133eTiP\n antibody-drug conjugate with a                                               Date/time: N/A\n topoisomerase 1 inhibitor payload, in\n patients with Claudin 18.2-expressing\n unresectable locally advanced or metastatic\n solid tumors\n FiH TiP: A phase 1 study of ASP5834 in                  S. Sen               Type: ePoster\n patients with locally advanced or metastatic                                 Abstract number: 1145eTiP\n solid tumors with Kirsten rat sarcoma viral                                  Date/time: N/A\n oncogene homologue (KRAS) mutations or\n amplifications\n Combination clinical data for mss CRC:                  V. Boni              Type: ePoster\n A phase 1/2 study of ASP1570 for locally                                     Abstract number: 1090eP\n advanced/metastatic microsatellite-stable                                    Date/time: N/A\n (MSS) colorectal cancer (CRC)\n\nAbout Astellas\nAstellas is a global life sciences company committed to turning innovative\nscience into value for patients. We provide transformative therapies in\ndisease areas that include oncology, ophthalmology, urology, immunology and\nwomen's health. Through our research and development programs, we are\npioneering new healthcare solutions for diseases with high unmet medical need.\nLearn more at www.astellas.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4790973-1&h=2550917136&u=http%3A%2F%2Fwww.astellas.com%2F&a=www.astellas.com)\n.\n\nAbout PADCEV and the Pfizer, Astellas and MSD Collaboration\nSeagen and Astellas previously entered a clinical collaboration agreement with\nMSD to evaluate the combination of Seagen's and Astellas'\nPADCEV(TM) (enfortumab vedotin) and MSD's KEYTRUDA(®) (pembrolizumab) in\npatients with urothelial cancer. Pfizer Inc. successfully completed its\nacquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark\nof Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,\nRahway, NJ, USA (known as MSD outside of the United States and Canada).\n\nAbout XTANDI and the Pfizer/Astellas Collaboration\nIn October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and\nAstellas (TSE: 4503) entered into a commercial agreement to jointly develop\nand commercialize XTANDI(®) (enzalutamide) in the United States, while\nAstellas has responsibility for manufacturing and all additional regulatory\nfilings globally, as well as commercializing the product outside the United\nStates. Pfizer receives alliance revenues as a share of U.S. profits and\nreceives royalties on sales outside the U.S.\n\nCautionary Notes\nIn this press release, statements made with respect to current plans,\nestimates, strategies and beliefs and other statements that are not historical\nfacts are forward-looking statements about the future performance of Astellas.\nThese statements are based on management's current assumptions and beliefs in\nlight of the information currently available to it and involve known and\nunknown risks and uncertainties. A number of factors could cause actual\nresults to differ materially from those discussed in the forward-looking\nstatements. Such factors include, but are not limited to: (i) changes in\ngeneral economic conditions, and in laws and regulations, relating to\npharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays\nin new product launches, (iv) the inability of Astellas to market existing and\nnew products effectively, (v) the inability of Astellas to continue to\neffectively research and develop products accepted by customers in highly\ncompetitive markets, and (vi) infringements of Astellas' intellectual property\nrights by third parties. Information about pharmaceutical products (including\nproducts currently in development) which is included in this press release is\nnot intended to constitute an advertisement or medical advice.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/astellas-highlights-data-advancing-cancer-care-and-innovation-for-patients-with-hard-to-treat-cancers-at-esmo-2026-302900206.html\n(https://www.prnewswire.com/news-releases/astellas-highlights-data-advancing-cancer-care-and-innovation-for-patients-with-hard-to-treat-cancers-at-esmo-2026-302900206.html)\n\nSOURCE Astellas Pharma Inc.\n\n\n\nAstellas Pharma Inc., Corporate Communications, +81-3-3244-3201\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS426384/Astellas-Logo.jpg?id=OA2990473\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-06T23:30:00.108497183Z","server_sent_at_ms":1791329400108},"received_at":"2026-10-06T23:30:00.278Z","source_url":"https://www.prnewswire.com/news-releases/astellas-highlights-data-advancing-cancer-care-and-innovation-for-patients-with-hard-to-treat-cancers-at-esmo-2026-302900206.html"},"analysis":{"id":"151033","press_release_id":"162550","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Astellas announced 21 abstracts for ESMO 2026 (October 23-27, Madrid), spanning PADCEV plus pembrolizumab in urothelial cancer, VYLOY/zolbetuximab in gastric cancer, and XTANDI in prostate cancer.\n\nFor Pfizer, the read-through is indirect: PFE earns alliance revenues as a share of U.S. XTANDI profits plus ex-U.S. royalties, and holds PADCEV rights via its December 2023 Seagen acquisition.\n\nNo new efficacy, safety, or financial figures were disclosed -- this is a congress-preview announcement, not a data readout.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Congress abstract preview with PFE indirect exposure only -- watch actual ESMO data on PADCEV/XTANDI later in October."},"keyFigures":{},"quotedText":"Pfizer receives alliance revenues as a share of U.S. profits and receives royalties on sales outside the U.S.","namedEntities":{"people":[{"name":"Naoki Okamura","role":"President and CEO, Astellas"},{"name":"Moitreyee Chatterjee-Kishore","role":"EVP and Head of Oncology Development, Astellas"}],"products":["PADCEV (enfortumab vedotin)","VYLOY (zolbetuximab)","XTANDI (enzalutamide)","KEYTRUDA (pembrolizumab)","setidegrasib","ASP5834","ASP546C","ASP1570"],"companies":[{"name":"Astellas Pharma Inc.","ticker":"4503","relationship":"partner / author of release"},{"name":"Pfizer Inc.","ticker":"PFE","relationship":"filer; XTANDI collaboration partner and PADCEV co-rights holder via Seagen acquisition"},{"name":"Merck & Co. (MSD)","relationship":"KEYTRUDA collaborator"},{"name":"Seagen","relationship":"acquired by Pfizer in 2023"},{"name":"Medivation, Inc.","relationship":"former XTANDI collaborator, now part of Pfizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Congress abstract-preview release authored by Astellas, not the filer. PFE has indirect exposure via XTANDI alliance revenues and PADCEV (through the Seagen acquisition), but no new data or figures are disclosed here."},"tickerRelevance":{"others":[{"ticker":"4503","relevance":"partner"}],"primary":"PFE"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"congress-abstract-preview","filerExposure":"indirect (XTANDI alliance, PADCEV via Seagen)","issuerAuthored":false}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"neutral","material_impact_score":2,"narrative":"Astellas announced 21 abstracts for ESMO 2026 (October 23-27, Madrid), spanning PADCEV plus pembrolizumab in urothelial cancer, VYLOY/zolbetuximab in gastric cancer, and XTANDI in prostate cancer.\n\nFor Pfizer, the read-through is indirect: PFE earns alliance revenues as a share of U.S. XTANDI profits plus ex-U.S. royalties, and holds PADCEV rights via its December 2023 Seagen acquisition.\n\nNo new efficacy, safety, or financial figures were disclosed -- this is a congress-preview announcement, not a data readout.","key_figures":{},"named_entities":{"people":[{"name":"Naoki Okamura","role":"President and CEO, Astellas"},{"name":"Moitreyee Chatterjee-Kishore","role":"EVP and Head of Oncology Development, Astellas"}],"products":["PADCEV (enfortumab vedotin)","VYLOY (zolbetuximab)","XTANDI (enzalutamide)","KEYTRUDA (pembrolizumab)","setidegrasib","ASP5834","ASP546C","ASP1570"],"companies":[{"name":"Astellas Pharma Inc.","ticker":"4503","relationship":"partner / author of release"},{"name":"Pfizer Inc.","ticker":"PFE","relationship":"filer; XTANDI collaboration partner and PADCEV co-rights holder via Seagen acquisition"},{"name":"Merck & Co. (MSD)","relationship":"KEYTRUDA collaborator"},{"name":"Seagen","relationship":"acquired by Pfizer in 2023"},{"name":"Medivation, Inc.","relationship":"former XTANDI collaborator, now part of Pfizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T23:30:06.267Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"mega-cap","eventGravity":"congress-abstract-preview","filerExposure":"indirect (XTANDI alliance, PADCEV via Seagen)","issuerAuthored":false}},"durationMs":6047,"modelName":"glm-5.3-flashx"}}